An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy

Cells. 2022 May 8;11(9):1583. doi: 10.3390/cells11091583.

Abstract

Tumor-associated macrophages (TAMs) accumulate in the solid tumor microenvironment (TME) and have been shown to promote tumor growth and dampen antitumor immune responses. TAM-mediated suppression of T-cell antitumor reactivity is considered to be a major obstacle for many immunotherapies, including immune checkpoint blockade and adoptive T/CAR-T-cell therapies. An ex vivo culture system closely mimicking the TME can greatly facilitate the study of cancer immunotherapies. Here, we report the development of a 3D TME-mimicry culture that is comprised of the three major components of a human TME, including human tumor cells, TAMs, and tumor antigen-specific T cells. This TME-mimicry culture can readout the TAM-mediated suppression of T-cell antitumor reactivity, and therefore can be used to study TAM modulation of T-cell-based cancer immunotherapy. As a proof-of-principle, the studies of a PD-1/PD-L1 blockade therapy and a MAO-A blockade therapy were performed and validated.

Keywords: CAR-engineered T (CAR-T) cell; cancer immunotherapy; checkpoint inhibitor blockade; chimeric antigen receptor (CAR); ex vivo 3D TME-mimicry culture; monoamine oxidase A (MAO-A) blockade; tumor microenvironment (TME); tumor-associated macrophage (TAM).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • Immunotherapy, Adoptive
  • Neoplasms* / drug therapy
  • Tumor Microenvironment*
  • Tumor-Associated Macrophages

Substances

  • Immune Checkpoint Inhibitors

Grants and funding

This work was supported by a Partnering Opportunity for Translational Research Projects Award from the California Institute for Regenerative Medicine (TRAN1-12250, to L.Y.), a UCLA BSCRC Innovation Award (to L.Y.), and an Ablon Scholars Award (to L.Y.).